Results 71 to 80 of about 8,118 (201)

Current and emerging treatment options for Graves’ hyperthyroidism

Therapeutics and Clinical Risk Management, 2009
Prakash Abraham1, Shamasunder Acharya21Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK; 2Department of Endocrinology, John Hunter Hospital, New Lambton NSW, AustraliaAbstract: Radioiodine, antithyroid drugs and surgery have been well ...
Prakash Abraham, Shamasunder Acharya
doaj  

Synthesis and Characterization of Sulfonamide‐Schiff Bases, and Investigation of Cytotoxic, Antioxidant, HDAC, and Apoptotic Activities in Human Colon Cancer Cells (DLD‐1 and HT‐29)

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
New sulfonamide‐Schiff bases were synthesized, characterized, and investigated for their cytotoxic, antioxidant, HDAC, and apoptotic activities in human colon cancer cells (DLD‐1 and HT‐29). Compounds 3c and 3d emerged as promising candidates to act as selective therapeutic agents by targeting the p38/MAPK‐ERK1 pathway in colorectal cancer.
Seda Mesci, Berna Kocaman, Aliye Gediz Erturk, Emine Bagdatli, Burak Yazgan, Tuba Yildirim   +5 more
wiley   +1 more source

Indefinite antithyroid drug therapy in toxic Graves′ disease: What are the cons

Indian Journal of Endocrinology and Metabolism, 2013
Existing treatment modalities for Graves′ disease includes antithyroid drugs (ATDs), radioactive iodine, and surgery. There has been a lack of general agreement as to which therapy is the best as none is ideal since all effectively restore euthyroidism ...
Rajesh Rajput, Vasudha Goel
doaj   +1 more source

Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Graves’ disease

Clinical Case Reports, 2021
We present a rare documented case with consecutive hypo‐ and hyperthyroidism during fetal life. First, hypothyroidism was due to transplacental passage of antithyroid drugs.
Hortense Didier‐Mathon, Hanane Bouchghoul, Marie‐Victoire Senat, Jacques Young, Dominique Luton   +4 more
doaj   +1 more source

Assessing Correlation of Quantitative Technetium‐99m Sestamibi Uptake in Thyroid Scintigraphy With Treatment Duration in Amiodarone‐Induced Thyrotoxicosis

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Ray Wang, Nathan Better, Dinesh Sivaratnam, James Westcott, Simon Forehan, David A. Pattison, Spiros Fourlanos   +6 more
wiley   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease

, 2015
Antithyroid drugs have been reported to reduce the expression of HLA-DR in thyrocytes in Graves' disease, but only circumstantial evidence has been provided about their in vivo immunologic effects.
Zantut-Wittmann, DE, Pinto, GA, Zantut-Wittmann, D E, Trevisan, MAD, Tambascia, M A, Vassallo, J, da Silva Trevisan, M A, Pinto, G A, Tambascia, MA   +8 more
core   +1 more source

Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves' disease

, 2022
Background: The aim of this study was to compare long-term mortality, morbidity, and cumulative healthcare costs between antithyroid drugs, radioactive iodine, and surgical treatment for patients with persistent or relapsed Graves' disease.
Liu, XD, Lam, CLK, Wong, CKH, Tang, HM, Chan, WLW, Woo, YC, Liu, SYW, Lang, HHB   +7 more
core   +1 more source

The evolving therapeutic landscape of Graves’ disease in adults: present and future

European Thyroid Journal
The therapeutic landscape of Graves’ hyperthyroidism has been rapidly evolving in the past few years. There has been a shift worldwide toward antithyroid drugs as the preferred first-line therapy with significant interest in thyroid function preservation,
Marius N Stan, Chrysoula Dosiou
doaj   +1 more source

Claustrum Sign in Hashimoto Encephalopathy Presenting With New Onset Refractory Status Epilepticus (NORSE): First Report of a Rare Phenotype

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT The presence of the bilateral claustrum sign in new‐onset refractory status epilepticus (NORSE) should prompt consideration of Hashimoto's encephalopathy, even without thyroid dysfunction. Early recognition and corticosteroid therapy can be lifesaving, emphasizing an autoimmune‐inflammatory mechanism underlying this rare presentation.
Zahra‐Sadat Mirian, Mohammad Amin Najafi, Alireza Anjam Majoumerd, Ali Khoshnevisan, Mohammad Reza Najafi   +4 more
wiley   +1 more source